This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Drug Stocks Poised to Surprise this Earnings Season
by Zacks Equity Research
Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.
Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.
Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.
Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.
Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.
Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?
by Zacks Equity Research
We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
by Zacks Equity Research
Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.
by Zacks Equity Research
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
by Zacks Equity Research
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
Top Research Reports for 16th January, 2017
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Accenture (ACN) and Eli Lilly (LLY).
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.
Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News
by Arpita Dutt
The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.
Trump Attacks Biotech & Pharma: ETFs Bleed
by Sweta Killa
Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.
Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo
by Zacks Equity Research
Eli Lilly and Company (LLY) and Merck & Co., Inc. (MRK) expanded their existing immuno-oncology partnership to include a new study that will evaluate Lilly???s Lartruvo in combination with Merck???s Keytruda in patients with STS.
Lilly Jardiance Family Diabetes Drugs' Label to be Updated
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.
Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit
by Zacks Equity Research
Eli Lilly and Company's (LLY) animal health subsidiary Elanco, announced that it has closed the previously announced acquisition of German drugmaker Boehringer Ingelheim's Vetmedica U.S. pet vaccines unit.
Two Key FDA Decisions to Watch Out for in January 2017
by Arpita Dutt
Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.
Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead
by Arpita Dutt
We advise investors to focus on biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis
by Zacks Equity Research
Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).
Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case
by Arpita Dutt
Lilly (LLY) was among the biggest gainers among major pharma stocks last week with the company providing better-than-expected guidance for 2017.
Company News for December 16, 2016
by Zacks Equity Research
Companies In The News are: MDLZ,KHC,LLY,PIR,APOG
Lilly Stock Surges on Robust 2017 View; Launches Basaglar
by Zacks Equity Research
Eli Lilly and Company (LLY) issued a better-than-expected financial guidance for 2017, alleviating investor concern to a large extent.
Company News for December 14, 2016
by Zacks Equity Research
Companies In the News are: PAY,LLY,BUD,PTEN,SSEIQ
Eli Lilly (LLY) to Offer Discount on Insulin from January
by Zacks Equity Research
Eli Lilly (LLY) announced that the company will offer access to its insulin products at discounted prices, starting Jan 2017.
Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy
by Zacks Equity Research
Eli Lilly and Company (LLY) announced the FDA approval of an extended-release formulation of its type II diabetes prescription drug Synjardy.